Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.23 USD | +1.65% | +17.14% | +123.64% |
Business Summary
Number of employees: 73
Managers
Managers | Title | Age | Since |
---|---|---|---|
René Russo
CEO | Chief Executive Officer | 49 | 19-05-21 |
Kevin Brennan
DFI | Director of Finance/CFO | 54 | - |
Chief Tech/Sci/R&D Officer | - | 22-09-30 | |
Chief Operating Officer | 42 | 21-02-28 | |
Uli Bialucha
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
Scott Coleman
PRN | Corporate Officer/Principal | - | 22-05-31 |
Stacey J. Davis
PRN | Corporate Officer/Principal | - | 22-05-16 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Clancy
CHM | Chairman | 62 | 20-07-22 |
Daniel Curran
BRD | Director/Board Member | 57 | 20-11-30 |
Tomas Jan Heyman
BRD | Director/Board Member | 68 | 22-09-14 |
Sara Bonstein
BRD | Director/Board Member | 43 | 21-08-16 |
Robert Ross
BRD | Director/Board Member | 50 | 22-06-15 |
René Russo
CEO | Chief Executive Officer | 49 | 19-05-21 |
Christina Rossi
BRD | Director/Board Member | 48 | 21-03-31 |
Yuan Xu
BRD | Director/Board Member | 56 | 22-01-03 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,917,834 | 25,916,324 ( 70.20 %) | 5,617 ( 0.0152 %) | 70.20 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+123.64% | 44.66M | |
+23.82% | 46.71B | |
+48.83% | 41.8B | |
-1.10% | 41.52B | |
-3.42% | 29.55B | |
+10.51% | 25.78B | |
-20.83% | 19.26B | |
+0.25% | 12.14B | |
-0.06% | 12.08B | |
+26.53% | 11.98B |
- Stock Market
- Equities
- XLO Stock
- Company Xilio Therapeutics, Inc.